Holen Sie sich die Stockscreener-App
3.40
0.89%
0.03
Handel nachbörslich:
3.40
Schlusskurs vom Vortag:
$3.37
Offen:
$3.35
24-Stunden-Volumen:
5,530
Relative Volume:
0.29
Marktkapitalisierung:
$2.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.29M
KGV:
-1.1209
EPS:
-3.0332
Netto-Cashflow:
$-9.42M
1W Leistung:
-0.58%
1M Leistung:
+16.04%
6M Leistung:
-13.27%
1J Leistung:
-51.43%
1-Tages-Spanne:
$3.35
$3.4999
1-Wochen-Bereich:
$3.20
$3.55
52-Wochen-Spanne:
$2.23
$8.92
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Firmenname
Scinai Immunotherapeutics Ltd Adr
Sektor
Branche
Telefon
972-8-9302529
Adresse
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Vergleichen Sie SCNI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
3.40 | 2.90M | 0 | -9.29M | -9.42M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Scinai Immunotherapeutics Ltd Adr Aktie (SCNI) Neueste Nachrichten
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports Nine-Month Financial Results - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) to Spotlight I&I Pipeline, CDMO Services at BIO-Europe 2024 - Barchart
Scinai Regains Full Compliance with Nasdaq Listing Requirements - Benzinga
Scinai secures $2 million investment commitment By Investing.com - Investing.com India
Today's Market - InvestorPlace
Taking on analysts’ expectations and winning: Scinai Immunotherapeutics Ltd ADR (SCNI) - SETE News
Scinai reports promising psoriasis treatment study - Investing.com
Heather Campe, Sr. VP at Fuller H B Co, sells shares worth over $1.9m By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: The Role of Supply and Demand - The InvestChronicle
Scinai reports promising psoriasis treatment study By Investing.com - Investing.com
Baird lowers Lululemon shares target on mixed U.S. traffic and spending By Investing.com - Investing.com India
Scinai Immunotherapeutics gets Nasdaq compliance extension By Investing.com - Investing.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI-Q) QuotePress Release - The Globe and Mail
Scinai reports Q1 results, progresses in pipeline By Investing.com - Investing.com South Africa
Scinai Immunotherapeutics (NASDAQ: SCNI) to Present at Europe Dermatology Drug Development Summit - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Receive $900K Grant for CDMO Business Unit - The Globe and Mail
Sezzle Inc. ex-director sells over $33,000 in company stock By Investing.com - Investing.com
Ambit Capital sets Buy rating on Mahindra & Mahindra shares By Investing.com - Investing.com India
Sunrise New Energy unveils new battery anode material By Investing.com - Investing.com
Bank lifts XPeng stock rating to neutral By Investing.com - Investing.com
BridgeBio shares set for quick recovery post HELIOS-B results - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Showcasing Services at Upcoming BIO-Europe Spring 2024 - The Globe and Mail
Nvidia CFO Colette Kress sells shares worth over $12 million By Investing.com - Investing.com
BeiGene COO Wu Xiaobin sells over $500k in company stock - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases FY 2023 Financial Results - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance - The Globe and Mail
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Should investors be concerned about SCNI’s high price-to-sales ratio? - US Post News
Scinai Immunotherapeutics (NASDAQ: SCNI) to Showcase CDMO Services at Premier CPHI Barcelona Event - The Globe and Mail
Scinai Immunotherapeutics Ltd ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Scinai receives EIB terms for loan-to-equity conversion By Investing.com - Investing.com
Atlassian co-CEO Cannon-Brookes sells over $1.29 million in company stock By Investing.com - Investing.com
Scinai regains Nasdaq compliance, eyes EIB loan conversion By Investing.com - Investing.com
Doris Matsui invests over $1 million in Intrinsic Exchange Group By Investing.com - Investing.com
Dream Finders Homes CEO sells over $960k in company stock By Investing.com - Investing.com
UBS cuts Cielo SA stock target, downgrades to neutral By Investing.com - Investing.com
Paramount and Charter extend distribution deal By Investing.com - Investing.com
Scinai Immunotherapeutics Battles Nasdaq Delisting - TipRanks
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma - The Globe and Mail
Biotech Rips Following Five-Year Master Service Agreement Release - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Agreement for Exercise of Outstanding Warrants - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases Q3 2023 Financial Report - The Globe and Mail
MARKET DATA - The Wall Street Journal
Hormel Foods Appoints Natosha Walsh VP of Marketing for Convenient Meals and Proteins - Investing.com India
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Scinai Immunotherapeutics Ltd Adr-Aktie (SCNI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):